PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
10.36%
Net income growth above 1.5x RVPH's 5.90%. David Dodd would see a clear bottom-line advantage if it is backed by stable operations.
-22.93%
Negative yoy D&A while RVPH is 0.00%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
18.38%
Deferred tax of 18.38% while RVPH is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
-40.28%
Both cut yoy SBC, with RVPH at -56.99%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
112.09%
Well above RVPH's 125.07% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
86.72%
AP growth well above RVPH's 101.70%. Michael Burry would be concerned about potential late payments or short-term liquidity strain relative to competitor.
300.21%
Growth well above RVPH's 159.63%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
-40.28%
Negative yoy while RVPH is 81.82%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
17.79%
Operating cash flow growth below 50% of RVPH's 38.83%. Michael Burry would see a serious shortfall in day-to-day cash profitability.
19.38%
CapEx growth of 19.38% while RVPH is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
99.99%
Growth of 99.99% while RVPH is zero at 0.00%. Bruce Berkowitz sees a moderate difference requiring justification by ROI in these smaller invests.
98.29%
We expand invests by 98.29% while RVPH is zero at 0.00%. Bruce Berkowitz sees a moderate outflow that must be justified by returns vs. competitor’s stable approach.
No Data
No Data available this quarter, please select a different quarter.
684.38%
Lower share issuance yoy vs. RVPH's 4129.39%, implying less dilution. David Dodd would confirm the firm still has enough capital for expansions.
No Data
No Data available this quarter, please select a different quarter.